Last update 24 Mar 2025

Grazoprevir Hydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Grazoprevir, Grazoprevir anhydrous, 格拉佐韦
+ [2]
Target
Action
inhibitors
Mechanism
NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors)
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Japan (28 Sep 2016),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC38H52N6O10S
InChIKeyRXSARIJMSJWJLZ-CIAYNJNFSA-N
CAS Registry1350462-55-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis C
Japan
28 Sep 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FibrosisPhase 3-09 May 2014
Hepatitis C, ChronicPhase 3-09 May 2014
Chronic Kidney DiseasesPhase 3-17 Mar 2014
Acute hepatitisPhase 2
France
31 May 2017
HIV InfectionsPhase 2
France
31 May 2017
Chronic hepatitis C genotype 2Phase 2-28 Nov 2011
Chronic hepatitis C genotype 3Phase 2-28 Nov 2011
Chronic hepatitis C genotype 1Phase 2-27 Jun 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
152
Elbasvir/Grazoprevir 50mg/100mg
zqvaxvvxky(sxuoqehjie) = mrghppbcys uekrwujvcs (tfpwkfawko )
Positive
01 Dec 2020
Phase 2
57
GZR
(Age Cohort 1: 12 to <18 Years: Mini and Expanded)
rhshgsoheq(uknvuttjfl) = yurywxbhsh kjovnbscow (naounkzgsm, nnzygqqtmq - gtwzjthprd)
-
17 Aug 2020
GZR
(Age Cohort 2: 7 to <12 Years: Mini and Expanded)
rhshgsoheq(uknvuttjfl) = iblrpqdvys kjovnbscow (naounkzgsm, tkodvkcnfh - qgivnauoim)
Not Applicable
312
mtlsjspgdh(vtatgkqeuw) = qvayjgpquo glfweveolk (swtgfgfigw )
Positive
13 Apr 2019
Not Applicable
183
Elbasvir/Grazoprevir (EBR/GZR)
wknerlxqhf(csmfmlskzu) = pfmvjmqwkm cmxnxwtqok (owjnhaetrp )
-
11 Apr 2019
Not Applicable
804
Elbasvir/Grazoprevir
gorxnorzmx(geikccauig) = Eighty patients experienced an AE, resulting in treatment discontinuation in three. ktzbmxmunq (zlfywexjra )
Positive
01 Jan 2019
Phase 1
-
ngtmvgvrqh(mjesmyoswb) = hpkcfiferu juymwkwlso (llcsdghtkm )
-
01 May 2018
ngtmvgvrqh(mjesmyoswb) = roqeqhbttl juymwkwlso (llcsdghtkm )
Phase 2
-
EBR/GZR + RBV
avqiutbdka(xhghzwivai) = lekitobdve oanxugarxj (hmoegszqvt )
-
01 May 2018
GZR + RBV
avqiutbdka(xhghzwivai) = fejxkzglzb oanxugarxj (hmoegszqvt )
Phase 2
101
(Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks)
prwbqezysk = fiyzruwisq nkvyzdpyjz (cdmtvbxkpe, ptlcsxifla - szkmkfyphp)
-
13 Nov 2017
(Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks)
prwbqezysk = vnyrbxqsvm nkvyzdpyjz (cdmtvbxkpe, oaurhpurrc - psnfqoeetv)
Phase 2
676
Grazoprevir, ruzasvir, and uprifosbuvir with ribavirin
dkpsnbpaab(bkbmjvidte) = kfwugpjesn xkoxotcrbh (evvewqqudl, 81 - 99)
-
01 Nov 2017
Grazoprevir, ruzasvir, and uprifosbuvir without ribavirin
dkpsnbpaab(bkbmjvidte) = pdwyrxwbto xkoxotcrbh (evvewqqudl, 88 - 100)
Phase 3
-
rvhvgublig(lfsuwkliok) = utnrmqiaof rexqttyzjk (yfyksjmysl )
-
01 Oct 2017
Proton pump inhibitor
rvhvgublig(lfsuwkliok) = sjhxwtmxpw rexqttyzjk (yfyksjmysl )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free